Granules India Peer Comparison

NSE: GRANULES | BSE: 532482

₹840.45

₹9.90 (1.19%)

As on 28-Oct-2026IST

Market cap

₹22,918 Cr

Revenue (TTM)

₹5,632 Cr

P/E Ratio

34.6

P/B Ratio

4.7

Div. Yield

0.2 %

Edit

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	22,918	31,084	30,346	30,994	25,908
Revenue (₹ Cr)	5,632	3,564	1,593	9,779	1,936
Net Profit (₹ Cr)	662.35	414.00	438.64	-270.51	288.22
Net Margin (%)	11.75	11.23	27.16	-2.71	14.79
RoE (%)	14.34	8.38	25.02	-2.55	29.77
Price to Earnings	34.60	76.00	69.10	--	89.89
Price-To-Book	4.68	6.17	16.34	3.81	19.30

Income Statement (₹ Cr)

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	5,632.31	3,564.00	1,592.52	9,778.62	1,935.80
Total Income	5,638.56	3,686.00	1,615.23	9,993.26	1,948.58
Total Expenditure	4,354.97	2,792.00	969.32	8,578.44	1,485.56
EBITDA	1,277.34	772.00	623.20	1,200.18	450.24
Depreciation	306.94	226.00	41.96	887.82	50.83
EBIT	970.39	546.00	581.24	312.36	399.41
Interest	111.70	217.00	4.21	347.94	40.84
Other Income	6.25	122.00	22.71	214.64	12.78
Exceptional Items	15.92	12.00	0.00	-216.88	0.00
Profit before Tax	880.86	463.00	599.74	-37.82	371.35
Provision for Tax	218.51	49.00	161.10	232.69	83.14
Profit after Tax	662.35	414.00	438.64	-270.51	288.22

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	5,085.00	4,940.00	1,857.45	8,142.24	1,288.82
Minority Interest	0.00	-5.00	0.51	0.55	0.00
Non-Current Liabilities	542.92	1,712.00	47.15	5,213.99	202.03
Current Liabilities	2,092.03	1,622.00	253.37	5,158.51	835.87
Total Liabilities	7,682.91	8,578.00	1,983.96	17,723.32	2,326.71

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	3,533.26	5,343.00	1,132.12	10,687.30	519.60
Current Assets	3,767.65	2,606.00	1,012.00	7,253.65	1,681.81
Total Assets	7,682.91	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	1,338.13	2,125.00	26.49	5,495.48	259.37
Net Current Assets	1,675.62	984.00	758.64	2,095.14	845.94
Contingent Liabilities	0.93	768.26	17.25	95.72	19.09

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	793.25	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	-773.21	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	379.29	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	399.33	95.00	30.33	787.59	78.39

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	15.74	6.79	32.42	1.24	29.22
ROE (%)	14.34	8.38	25.02	-2.55	29.77
ROA (%)	9.48	4.94	22.40	-1.56	24.77
EBIT Margin (%)	17.23	15.32	36.50	3.19	20.63
Net Margin (%)	11.75	11.23	27.16	-2.71	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	24.83	18.37	45.18	9.43	46.65
EBIT Growth (%)	40.39	252.26	115.51	-3.72	62.13
Net Profit Growth (%)	38.13	377.85	95.80	-199.34	89.49
EPS Growth (%)	34.88	1,001.33	63.29	-410.28	78.60
Book Value Growth (%)	27.49	13.47	26.03	0.33	144.31

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	31.73	78.00	69.10	-149.04	88.51
Price / Book Value	4.68	6.17	16.34	3.81	19.30
Dividend Yield (%)	0.21	0.00	0.07	0.00	0.10
EV/EBITDA	18.25	42.16	48.37	29.27	57.35
Market Cap (₹ Cr)	15,391.88	19,071.62	20,944.75	18,108.89	12,753.19

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.06	0.31	0.02	0.55	0.11
Short term debt to equity ratio	0.20	0.09	0.00	0.09	0.05
Current Ratio	1.80	1.61	3.99	1.41	2.01
Quick Ratio	1.00	1.06	2.89	0.77	1.14
Interest Coverage	8.89	3.13	143.52	0.89	10.09

	Granules India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	16.15	16.50	22.50	23.05	26.28
Asset Turnover	0.81	0.43	0.81	0.56	1.66
Receivable days	33.72	58.75	88.98	78.20	40.13
Inventory Days	54.92	75.82	56.04	93.30	60.29
Payable days	136.11	186.21	99.95	226.14	232.47
Cash Conversion Cycle	-47.47	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.